ArticleBMC gastroenterology2026
GCKR genetic variants and circulating FGF21 identify a metabolic risk signature in metabolic dysfunction-associated steatotic liver disease.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver-nervous system axis in MASLD: mechanistic insights and emerging targeted therapies.eGastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsInterindividual variability in metabolic dysfunction–associated steatotic liver disease (MASLD) onset and its progressive inflammatory stage, metabolic dysfunction–associated steatohepatitis (MASH), reflects a complex interplay between metabolic burden and inherited susceptibility. We investigated the combined impact of genetic variants in the glucokinase regulatory protein gene (GCKR) and fibroblast growth factor 21 (FGF21), together with circulating FGF21 concentrations, on susceptibility to MASLD and its progression to MASH.
methodsThis case-control study enrolled 150 patients with MASLD, 150 patients with clinically suspected MASH, and 150 age- and sex-matched healthy controls. Genotyping of GCKR rs1260326 and FGF21 rs838133 polymorphisms was performed using DNA extracted from peripheral blood samples by real-time polymerase chain reaction, while serum FGF21 levels were quantified by enzyme-linked immunosorbent assay. Associations with metabolic characteristics, liver function indices, and fibrosis severity were examined using correlation analyses and multivariate logistic regression models.
resultsThe GCKR rs1260326 TT genotype and T allele carriers had an increased risk of MASH progression versus MASLD (AOR for TT genotype: 16.875; 95% CI: 6.339–44.921, P = 0.001), adjusted for age, sex, BMI, HOMA-IR and triglycerides level. Moreover, the TT genotype was associated with higher alanine aminotransferase levels and reduced markers of hepatic synthetic capacity. In parallel, carriers of AG genotype of FGF21 rs838133 exhibited a higher propensity for progression to MASLD (AOR: 18.622; 95% CI: 1.619-214.169, P = 0.019) and G allele accompanied by greater insulin resistance and unfavorable lipid profiles. Circulating FGF21 concentrations demonstrated a stepwise increase from controls to MASLD and MASH groups and showed good discriminatory performance in differentiating MASLD from controls (AUC = 0.821) and excellent accuracy in identifying MASH among healthy individuals (AUC = 0.929).
conclusionsGenetic variation in GCKR and FGF21, together with altered hepatokine signaling, contributes substantially to metabolic dysregulation and liver disease severity. Integrating genetic profiling with circulating biomarkers may offer a refined strategy for identifying individuals at high risk of MASLD progression and advancing precision-based approaches in metabolic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.